Raymond Palmer
Raymond D. Palmer is an Australian researcher based in South Perth, Western Australia. He is the Chief Science Officer of Full Spectrum Biologics, and formerly CSO of Helium‐3 Biotech.1) 2)
On his LinkedIn profile, Palmer describes himself as a longevity researcher, biotech engineer, mRNA alchemist, astronomer, and an author.3)
Activities
Palmer has co-authored research with Ione Swanepoel, April Roberts, Chelsea Brauns, Devahuti Chaliha, Veronica Papa, Magdy Mahmoud Elnashar and Mauro Vaccarezza.4) 5)
COVID-19
On September 1, 2022, a mini-review authored by Palmer was published online by the journal BioMedicine in which he argues that side effects following COVID-19 vaccination can be attributed to stress caused by “fear mongering and scare tactics used by various anti-vaccination groups.”6)
1)
, 6)
Palmer, R. (2022). Covid19 Vaccines and the Misinterpretation of Perceived Side Effects. BioMedicine, 12(3), 1–4. https://doi.org/10.37796/2211-8039.1371
2)
, 4)
Palmer, R. D., Elnashar, M. M., & Vaccarezza, M. (2021). Precursor comparisons for the upregulation of nicotinamide adenine dinucleotide. Novel approaches for better aging. AGING MEDICINE, 4(3), 214–220. https://doi.org/10.1002/agm2.12170
3)
Raymond D Palmer. LinkedIn. Retrieved November 27, 2022, from https://www.linkedin.com/in/palmerray/
5)
Swanepoel, I., Roberts, A., Brauns, C., Chaliha, D. R., Papa, V., Palmer, R. D., & Vaccarezza, M. (2021). Trimethylamine N-oxide (TMAO): a new attractive target to decrease cardiovascular risk. Postgraduate Medical Journal, 98(1163), 723–727. https://doi.org/10.1136/postgradmedj-2021-139839